Latest Breaking News On - ஔட்‌கம் அளவு - Page 1 : comparemela.com

Share this article Share this article SUZHOU, China, Jan. 10, 2021 /PRNewswire/ Kintor Pharmaceutical Limited (HKEX: 9939) is pleased to update the preliminary analysis of the clinical trial of Proxalutamide for the treatment of COVID-19 patients. The investigator initiated trial conducted by Dr. Andy Goren and Dr. Flávio Adsuara Cadegiani, shows promising results in the treatment of COVID-19 female outpatients. This trial commenced the enrolment of 168 female patients on Nov, 2020 after receiving the encouraging results from male patients. Eligible female patients were randomized in a 2:1 ratio to receive either Proxalutamide + standard care (Proxalutamide arm) or Placebo + standard care (Control arm). The co-primary endpoints of the clinical trial are the percentage of subjects hospitalized with COVID-19 and the COVID-19 Ordinal Outcome Scale (a 8-point ordinal scale used by the US National Institute of Allergy and Infection Diseases, such as mechanical ventilation usage and

Andy gorenCarlos gustavo wambierJohn mccoyAdsuara cadegianiUs national institute of allergyMinistry of healthKintor pharmaceuticalPrnewswire kintor pharmaceutical limitedPharmaceutical limitedOutcome scaleInfection diseasesTong youzhiCov protocol pioneeredApplied biologyBrazilian scientists adoptedKintor pharmaceutical limited